Use my Search Websuite to scan PubMed, PMCentral, Journal Hosts and Journal Archives, FullText. Kick-your-searchterm to multiple Engines kick-your-query now !>

A dictionary by aggregated review articles of nephrology, medicine and the life sciences Your one-stop-run pathway from word to the immediate pdf of peer-reviewed on-topic knowledge.

10.1016/j.mehy.2020.110161 http://scihub22266oqcxt.onion/10.1016/j.mehy.2020.110161 32795832!7403158!32795832     free     free     free Deprecated: Implicit conversion from float 211.6 to int loses precision in C:\Inetpub\vhosts\kidney.de\httpdocs\pget.php on line 534 Deprecated: Implicit conversion from float 211.6 to int loses precision in C:\Inetpub\vhosts\kidney.de\httpdocs\pget.php on line 534 Deprecated: Implicit conversion from float 211.6 to int loses precision in C:\Inetpub\vhosts\kidney.de\httpdocs\pget.php on line 534       Med+Hypotheses 2020 ; 144 (ä): 110161 Nephropedia Template TP {{tp|p=32795832|t=2020. Mitochondrial-targeted ubiquinone: A potential treatment for COVID-19 |pdf=|usr=}}{{32795832}} gab.com Text Mitochondrial-targeted ubiquinone: A potential treatment for COVID-19 JO: Med Hypotheses http://www.kidney.de/pget.php?&tw=1&pmid=32795832 #FOAvip Immune dysregulation characterized by T cell exhaustion and high level of inflammatory cytokines is associated with severe COVID-19. Figuring out the early event of immune dysregulation would provide a potential treatment for COVID-19. Recent evidence indicate that mitochondrial dysfunction participates in the development of COVID-19 and may be responsible for the dysregulated immune response. Mitochondrial-targeted ubiquinone (MitoQ), a mitochondrial-targeted antioxidant, shows beneficial effects on various diseases through improving mitochondrial dysfunction. We hypothesize that MitoQ could act as a potential treatment in COVID-19. MitoQ may alleviate cytokine storm and restore the function of exhausted T cells in COVID-19 patients through improving mitochondrial dysfunction. In this article, we provide evidence to support the use of MitoQ as a potential treatment or adjunct therapy in the context of COVID-19. Twit Text FOAVip Mitochondrial-targeted ubiquinone: A potential treatment for COVID-19 ????Med Hypotheses http://www.kidney.de/pget.php?&tw=1&pmid=32795832 #FOAvip Twit Text # Free Paper on # # # # # LINK http://www.kidney.de/pget.php?&tw=1&pmid=32795832 #FOAvip English Wikipedia <ref>{{Cite pmid|32795832}}</ref> Mitochondrial-targeted ubiquinone: A potential treatment for COVID-19 #MMPMID32795832 Ouyang L; Gong J Med Hypotheses 2020[Nov]; 144 (ä): 110161 PMID32795832show ga Immune dysregulation characterized by T cell exhaustion and high level of inflammatory cytokines is associated with severe COVID-19. Figuring out the early event of immune dysregulation would provide a potential treatment for COVID-19. Recent evidence indicate that mitochondrial dysfunction participates in the development of COVID-19 and may be responsible for the dysregulated immune response. Mitochondrial-targeted ubiquinone (MitoQ), a mitochondrial-targeted antioxidant, shows beneficial effects on various diseases through improving mitochondrial dysfunction. We hypothesize that MitoQ could act as a potential treatment in COVID-19. MitoQ may alleviate cytokine storm and restore the function of exhausted T cells in COVID-19 patients through improving mitochondrial dysfunction. In this article, we provide evidence to support the use of MitoQ as a potential treatment or adjunct therapy in the context of COVID-19. |*COVID-19 Drug Treatment[MESH] |Cytokines/metabolism[MESH] |Humans[MESH] |Immune System[MESH] |Mitochondria/*drug effects[MESH] |Models, Theoretical[MESH] |Organophosphorus Compounds/*therapeutic use[MESH] |Reactive Oxygen Species/metabolism[MESH] |Treatment Outcome[MESH]Mitochondrial-targeted ubiquinone: A potential treatment for COVID-19 (epmc).pdf DeepDyve Pubget Overpricing